Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript
Sight Sciences (SGHT) reported Q2 2026 revenue of $23.4M, up 20% y/y, driven by Interventional Glaucoma ($20.7M) and Interventional Dry Eye ($2.7M). Gross margin rose to 91% from 85%. Net loss was $4.4M. FY2026 revenue guidance raised to $88M-$92M; adjusted opex guidance lowered to $92M-$94M. Alcon patent appeal remains pending.
How this was made
The 30-second read
Why it matters
The key tradable elements are the raised FY2026 revenue guidance, lowered adjusted operating expense guidance, and the explicit risk that Alcon has appealed and no cash has been received yet. Management also highlighted reimbursement expansion (Aetna) and upcoming OMNI Ultra launch after FDA 510(k) clearance.
Market read
Traders can reprice SGHT on the combination of guidance upside, improving operating expense trajectory, and reimbursement scaling, while monitoring cash burn and litigation cash timing.
What to watch
TearCare growth metrics (patient lives, ordering accounts, SmartLids utilization) are strong, but the article does not quantify durability of reimbursement expansion beyond Aetna or provide competitive outcome data beyond the stated RCT claim.
Background
Sight Sciences reported Q2 2026 results for its interventional glaucoma and interventional dry eye platforms, alongside litigation updates and product development progress.
Ticker impact
Sight Sciences raised FY2026 revenue guidance to $88M-$92M and narrowed expense guidance after reporting Q2 revenue of $23.4M and improved net loss.
Near-term bias upward if investors focus on raised revenue and narrowed expense range; downside risk if cash burn and Alcon appeal overhang dominate.
The article provides multiple decision-useful datapoints: raised revenue guidance, narrowed glaucoma guidance, reduced adjusted operating expense guidance, and a clear litigation cash timing risk (no cash received yet due to appeal).
Market effects
Supports a constructive read-through for ophthalmic medtech adoption and reimbursement scaling, especially for MIGS and dry-eye procedural platforms.
Limited direct regional impact; primarily US reimbursement and FDA-cleared product rollout narrative.
Moderate, as reimbursement and FDA clearance are US-centric but can influence global investor sentiment toward eye-care device adoption.
Counterpoint
The gross margin uplift is partly driven by one-time tariff refunds, and cash still fell sequentially; the Alcon appeal means the $55M judgment cash timing remains uncertain.
Key entities
- companySight Sciences
US-listed ophthalmic device company reporting Q2 2026 results and raising FY2026 guidance.
- counterpartyAlcon
Patent litigation defendant; appeal is pending and cash from the judgment has not been received yet.
- payerAetna
Added 25M commercial covered lives for OMNI and SION procedures after recognizing certain implant-free glaucoma procedures as medically necessary.
- productOMNI Ultra Surgical System
Implant-free minimally invasive glaucoma surgery technology; management plans launch later this year after FDA 510(k) clearance.
